Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta(University of Pennsylvania), Christopher L. Nobles(University of Pennsylvania), Morgan A. Sammons(University at Albany, State University of New York), Stefan Lundh(University of Pennsylvania), Shannon A. Carty(University of Pennsylvania), Tyler J. Reich(University of Pennsylvania), Alexandria P. Cogdill(University of Pennsylvania), Jennifer J.D. Morrissette(University of Pennsylvania), Jamie E. DeNizio(University of Pennsylvania), Shantan Reddy(University of Pennsylvania), Young Sun Hwang(University of Pennsylvania), Mercy Gohil(University of Pennsylvania), Irina Kulikovskaya(University of Pennsylvania), Farzana Nazimuddin(University of Pennsylvania), Minnal Gupta(University of Pennsylvania), Fang Chen(University of Pennsylvania), J.K. Everett(University of Pennsylvania), Katherine A. Alexander(University of Pennsylvania), Enrique Lin-Shiao(University of Pennsylvania), Marvin H. Gee(Stanford University), Xiaojun Liu(University of Pennsylvania), Regina M. Young(University of Pennsylvania), David E Ambrose(University of Pennsylvania), Yan Wang(University of Pennsylvania), Jun Xu(University of Pennsylvania), Martha S. Jordan(University of Pennsylvania), Katherine T. Marcucci(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), K. Christopher García(Stanford University), Yangbing Zhao(University of Pennsylvania), Michael Kalos(University of Pennsylvania), David Porter(University of Pennsylvania), Rahul M. Kohli(University of Pennsylvania), Simon F. Lacey(University of Pennsylvania), Shelley L. Berger(University of Pennsylvania), Frederic D. Bushman(University of Pennsylvania), Carl H. June(University of Pennsylvania), J. Joseph Melenhorst(University of Pennsylvania)
Cited by 856Open Access